PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway. This can result in the promotion of precancerous lesions and secondary neoplasms,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tutuka, Candani S. A., Andrews, Miles C., Mariadason, John M., Ioannidis, Paul, Hudson, Christopher, Cebon, Jonathan, Behren, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490236/
https://www.ncbi.nlm.nih.gov/pubmed/28659148
http://dx.doi.org/10.1186/s12943-017-0684-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490236/
https://www.ncbi.nlm.nih.gov/pubmed/28659148
http://dx.doi.org/10.1186/s12943-017-0684-x

Ejemplares similares